News
LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...
JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
1d
NDTV Profit on MSNCipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug SectorCipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...
In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...
In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...
One person using Mounjaro revealed they had a peculiar ‘magic mushroom’ sensation when starting the medication in a discussion about side effects on Reddit ...
Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results